Terms: = Lung cancer AND ERBB4, MGC138404, 2066, ENSG00000178568, Q15303, p180erbB4, HER4 AND Prognosis
26 results:
1. Architecting the metabolic reprogramming survival risk framework in LUAD through single-cell landscape analysis: three-stage ensemble learning with genetic algorithm optimization.
Sun X; Nong M; Meng F; Sun X; Jiang L; Li Z; Zhang P
J Transl Med; 2024 Apr; 22(1):353. PubMed ID: 38622716
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic Value and Genome Signature of m6A/m5C Regulated Genes in Early-Stage lung Adenocarcinoma.
Tian L; Wang Y; Tian J; Song W; Li L; Che G
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047493
[TBL] [Abstract] [Full Text] [Related]
3. Tastin promotes non-small-cell lung cancer progression through the erbb4, PI3K/AKT, and ERK1/2 pathways.
Yue A; Chen M; Dai S; Zhang Y; Wei W; Fan L; Wang F; Zhang F; Yu H; Lu Y; Lei Y
Exp Biol Med (Maywood); 2023 Mar; 248(6):519-531. PubMed ID: 36691332
[TBL] [Abstract] [Full Text] [Related]
4. Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract.
Wu H; Yu Z; Liu Y; Guo L; Teng L; Guo L; Liang L; Wang J; Gao J; Li R; Yang L; Nie X; Su D; Liang Z
Cancer Commun (Lond); 2022 Dec; 42(12):1367-1386. PubMed ID: 36264285
[TBL] [Abstract] [Full Text] [Related]
5. Identification of genes and pathways associated with sex in Non-smoking lung cancer population.
Xu L; Wang L; Cheng M
Gene; 2022 Jul; 831():146566. PubMed ID: 35577039
[TBL] [Abstract] [Full Text] [Related]
6. The role of erbb4 mutations in the prognosis of advanced non-small cell lung cancer treated with immune checkpoint inhibitors.
Hu X; Xu H; Xue Q; Wen R; Jiao W; Tian K
Mol Med; 2021 Oct; 27(1):126. PubMed ID: 34620079
[TBL] [Abstract] [Full Text] [Related]
7. Association of erbb4 genetic polymorphism with the risk and prognosis of non-small cell lung cancer in Chinese Han population: A population-based case-control study.
Wang WP; Bian HB; Wang XZ; Liu L; Wei D
Medicine (Baltimore); 2021 May; 100(19):e25762. PubMed ID: 34106605
[TBL] [Abstract] [Full Text] [Related]
8. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
[TBL] [Abstract] [Full Text] [Related]
9. MicroRNA-936/erbb4/Akt axis exhibits anticancer properties of gastric cancer through inhibition of cell proliferation, migration, and invasion.
Liu S; Gong Y; Xu XD; Shen H; Gao S; Bao HD; Guo SB; Yu XF; Gong J
Kaohsiung J Med Sci; 2021 Feb; 37(2):111-120. PubMed ID: 33021020
[TBL] [Abstract] [Full Text] [Related]
10. Comparison of oral versus intravenous etoposide in the management of small-cell lung cancer; A real-world, population-based study.
Karachiwala H; Tilley D; Abdel-Rahman O; Morris D
Clin Respir J; 2021 Jan; 15(1):36-41. PubMed ID: 32803870
[TBL] [Abstract] [Full Text] [Related]
11. [SMARCA4-deficient primary thoracic sarcoma:a clinicopathological analysis of five cases].
Zheng MJ; Zheng Q; Wang Y; Shen L; Zhu XZ; Li Y
Zhonghua Bing Li Xue Za Zhi; 2019 Jul; 48(7):537-542. PubMed ID: 31288309
[No Abstract] [Full Text] [Related]
12. Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell lung cancer.
Kang J; Luo Y; Wang D; Men Y; Wang J; Che YQ; Hui Z
Dis Markers; 2019; 2019():3837687. PubMed ID: 31182981
[TBL] [Abstract] [Full Text] [Related]
13. Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.
Wang W; Zhao HF; Yao TF; Gong H
Invest New Drugs; 2019 Feb; 37(1):175-183. PubMed ID: 30353245
[TBL] [Abstract] [Full Text] [Related]
14. ErbB Receptors and cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract] [Full Text] [Related]
15. Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing.
Cho SY; Choi M; Ban HJ; Lee CH; Park S; Kim H; Kim YS; Lee YS; Lee JY
Oncotarget; 2017 Jan; 8(5):8095-8104. PubMed ID: 28042953
[TBL] [Abstract] [Full Text] [Related]
16. Hot spot mutations in Finnish non-small cell lung cancers.
Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
[TBL] [Abstract] [Full Text] [Related]
17. EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma.
Chen HY; Liu CH; Chang YH; Yu SL; Ho BC; Hsu CP; Yang TY; Chen KC; Hsu KH; Tseng JS; Hsia JY; Chuang CY; Chang CS; Li YC; Li KC; Chang GC; Yang PC
Oncotarget; 2016 Feb; 7(8):9017-25. PubMed ID: 26824984
[TBL] [Abstract] [Full Text] [Related]
18. LncRNA-UCA1 exerts oncogenic functions in non-small cell lung cancer by targeting miR-193a-3p.
Nie W; Ge HJ; Yang XQ; Sun X; Huang H; Tao X; Chen WS; Li B
Cancer Lett; 2016 Feb; 371(1):99-106. PubMed ID: 26655272
[TBL] [Abstract] [Full Text] [Related]
19. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract] [Full Text] [Related]
20. Prognostic significance of serum ERBB3 and erbb4 mRNA in lung adenocarcinoma patients.
Masroor M; Javid J; Mir R; Y P; A I; Z M; Mohan A; Ray PC; Saxena A
Tumour Biol; 2016 Jan; 37(1):857-63. PubMed ID: 26254096
[TBL] [Abstract] [Full Text] [Related]
[Next]
